Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Dalantercept (ACE-041)
print preview
bookmark
share with colleague
General Information
Company
Acceleron Pharma Inc.
Description
Angiogenesis inhibitor that binds to and prevents members of the transforming growth factor (TGF) beta superfamily from signaling through ALK1
Molecular Target
Activin receptor-like kinase 1 (ACVRL1) (ALK1) (HHT2)
Mechanism of Action
Angiogenesis inhibitor
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Disease Category
Standard Indication
Indication Details
Partners
Milestones
Latest Stage of Development
More
Archive Items are loading
Set Email Alert
dummy